These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 30136247)
1. Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease. Lim J; Bang Y; Choi HJ Arch Pharm Res; 2018 Oct; 41(10):943-954. PubMed ID: 30136247 [TBL] [Abstract][Full Text] [Related]
2. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease. Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622 [TBL] [Abstract][Full Text] [Related]
3. Adult neurogenesis in Parkinson's disease. Marxreiter F; Regensburger M; Winkler J Cell Mol Life Sci; 2013 Feb; 70(3):459-73. PubMed ID: 22766974 [TBL] [Abstract][Full Text] [Related]
11. ALCAR promote adult hippocampal neurogenesis by regulating cell-survival and cell death-related signals in rat model of Parkinson's disease like-phenotypes. Singh S; Mishra A; Mishra SK; Shukla S Neurochem Int; 2017 Sep; 108():388-396. PubMed ID: 28577987 [TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease: Autoimmunity and neuroinflammation. De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913 [TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. Chiu WH; Depboylu C; Hermanns G; Maurer L; Windolph A; Oertel WH; Ries V; Höglinger GU Neuropharmacology; 2015 Aug; 95():367-76. PubMed ID: 25839898 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment. Bang Y; Lim J; Choi HJ Arch Pharm Res; 2021 Jun; 44(6):588-604. PubMed ID: 34145553 [TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease. Yamashita H; Matsumoto M Regen Med; 2007 Jul; 2(4):447-55. PubMed ID: 17635051 [TBL] [Abstract][Full Text] [Related]
16. Harnessing neurogenesis for the possible treatment of Parkinson's disease. Lamm O; Ganz J; Melamed E; Offen D J Comp Neurol; 2014 Aug; 522(12):2817-30. PubMed ID: 24723264 [TBL] [Abstract][Full Text] [Related]
17. Episodic recognition memory and the hippocampus in Parkinson's disease: A review. Das T; Hwang JJ; Poston KL Cortex; 2019 Apr; 113():191-209. PubMed ID: 30660957 [TBL] [Abstract][Full Text] [Related]
18. Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume. van Mierlo TJ; Chung C; Foncke EM; Berendse HW; van den Heuvel OA Mov Disord; 2015 Feb; 30(2):245-52. PubMed ID: 25600157 [TBL] [Abstract][Full Text] [Related]
19. Neurobiology of depression in Parkinson's disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ahmad MH; Rizvi MA; Ali M; Mondal AC Ageing Res Rev; 2023 Mar; 85():101840. PubMed ID: 36603690 [TBL] [Abstract][Full Text] [Related]
20. Dopamine agonists in the treatment of non-motor symptoms of Parkinson's disease: depression. Lemke MR Eur J Neurol; 2008 Sep; 15 Suppl 2():9-14. PubMed ID: 18702737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]